OUR MISSION AND VALUES

ACCELERATE

OUR MISSION

OUR STORY

OUR VALUES

OUR MISSION

Lives can be transformed when the strength of academic and business combine. As a biomedical institute, we act as a catalyst and a driver, forming dynamic partnerships to unlock the power of emerging discoveries. The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme, which aims to transform pioneering science into therapies.

We are a physical hub that combines the strength of academia and business to accelerate the development of therapies. Our own in-house research programme in the Centre for Pathway Analysis builds a mass of expertise in computational research and functional genomics, with a growing network of collaborative research partners.

We support entrepreneurs through our Frame Shift Bio-incubator, in partnership with the Start Codon Venture Builder and Investor, and through the growth of Connect: Health Tech. We also work with other University organizations to create a wealth of resources and commercial support for academics seeking to put ideas into practice.

Our institute is the headquarters of the Milner Therapeutics Consortium. Now with eleven pharma partners and three academic partners, this provides a unique and diverse set of ways for our partners to engage with Cambridge academics and entrepreneurs. By creating innovative models of cross-sector collaboration locally, the Milner community can provide a leading international example of how academic discoveries can be brought out of the lab towards effective therapies.

OUR STORY

The Milner Therapeutics Institute was founded in 2015 as a new paradigm for an academic Institution, based on bridging the gap between academia and Industry. The research institute opened in summer 2019 in the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for these cross-sector collaborations.

 

 

 

 

Our mission is to transform pioneering science into therapies by catalysing partnerships between academia and industry

The Milner Therapeutics Institute was co-founded by Tony Kouzarides and Jonathan Milner, and the therapeutics concept and mission was developed following the establishment of the Milner Therapeutics Consortium by Tony Kouzarides.  Jonathan Milner is a benefactor to the building of the Research Institute, which bears his name.  Tony and Jonathan are also co-founders of Abcam plc, an antibody reagents provider based in Cambridge.

OUR VALUES

We are ambitious
Our aim is to bring discoveries to life by unlocking the power of emerging discoveries, and galvanising science into life-changing treatments. We are the only Institute globally to our knowledge that brings together our unique combination of cross-sector capabilities.

We are here for you
We lower barriers to engagement by driving connections, welcoming fresh ideas, embracing flexibility, and ensuring we are approachable. We our vast network of knowledge and expertise to support academics and businesses in Cambridge and beyond.

We believe in the power of collaboration 
Lives can be transformed when the strength of academia and business combine. We have created a unique physical environment where pharma, start-ups and academics are co-located to drive collaboration and bring research discoveries out of the lab and towards new therapies.

We invest in our people
In our community, we seek and respect diversity, practice inclusivity, and uphold values of equality. We promote an environment that is a safe space for mistakes, where successes are celebrated, and where team members and collaborators support one another to reach their full potential.